Physician profile
Jonathan W Buttram
NPI 1497714984
$5,753.27
in general payments reported to CMS, 2019-2025
29 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $234 · 2021: $684 · 2022: $1,118 · 2023: $1,035 · 2024: $699 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.69 |
| Education | $100.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $919.72 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $807.79 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $597.75 | 2021-2025 | Takhzyro, Eohilia, Cuvitru |
| Glaxosmithkline, LLC. | $581.94 | 2021-2025 | Nucala |
| Grifols USA, LLC | $506.43 | 2022-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $355.92 | 2019-2025 | |
| Genzyme Corporation | $268.55 | 2022-2025 | |
| Pfizer INC. | $216.54 | 2020-2025 | |
| Csl Behring | $199.19 | 2022-2025 | Hizentra, Privigen, Haegarda |
| Alk-Abello, INC | $187.03 | 2019 | |
| Kaleo, INC. | $153.42 | 2020-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $131.88 | 2019-2021 | |
| Genentech USA, INC. | $131.25 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $110.74 | 2023-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $66.48 | 2025 | Orladeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64.63 | 2022-2024 | Rinvoq |
| Teva Pharmaceuticals USA, INC. | $62.37 | 2021 | |
| Amgen INC. | $57.00 | 2019-2025 | |
| Shire North American Group INC | $48.04 | 2019 | |
| Hospira, INC. | $42.43 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $40.89 | 2025 | Zoryve |
| Biocryst Pharmaceuticals, INC. | $38.17 | 2020 | |
| Lilly USA, LLC | $29.57 | 2025 | Taltz, Ebglyss |
| Paratek Pharmaceuticals, INC. | $28.09 | 2025 | Xhance |
| Incyte Corporation | $26.34 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $25.40 | 2025 | Neffy |
| Blueprint Medicines Corporation | $24.17 | 2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $18.39 | 2025 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Buttram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.